5% per year [6] These and other findings have raised doubt about

5% per year [6]. These and other findings have raised doubt about the relevance of BE as precancerous lesion of EACs (e.g. [7]), stimulation the search for the cell population, from which EACs originate and which is currently unknown. Two cancer models have been put forward to explain tumor GS-9973 order heterogeneity and inherent differences of tumor-regenerating capacity [8]. The clonal selection model of carcinogenesis implies that a random solitary cell undergoes malignant transformation, accumulates multiple mutations and subsequently acquires a survival advantage, which leads to clonal selection [9, 10]. In contrast, the cancer stem cell (CSC) hypothesis regards

malignant transformation as a process, occurring in a subset of normal stem cells with GF120918 in vivo pluripotent properties, which underlie deregulation of self-renewal pathways GSK2118436 purchase [11, 12]. Evidence is accumulating that most, if not all, malignancies are driven by a cancer stem cell compartment [8]. The existence of cancer stem cells would explain why only a small minority of cancer cells is capable of extensive proliferation within the tumor. Furthermore, these cancer stem cells may be inherently resistant to our current therapeutic approaches.

It is important to note that the two models are not mutually exclusive, as CSCs themselves may undergo clonal evolution, as already shown for leukaemia cells [13, 14]. A stem cell hypothesis for BE has also been put forward by the group around Spechler [13]. It has been proposed that specialized intestinal metaplasia could arise from a change in the differentiation pattern of stem cells that might either reside Chloroambucil in the esophagus or which might be recruited to the esophagus from the bone marrow [13]. A putative intestinal stem cell marker has been proposed to be potentially implicated in carcinogenesis of BE and EAC, but have so far not been thoroughly investigated. Leucine-rich-repeat-containing G-protein-coupled receptor (LgR5) has been shown to be associated with intestinal stem cell properties [15–18]. The aim of our study was to investigate expression of this putative intestinal stem cell marker in esophageal

adenocarcinomas (EAC) with and without associated intestinal metaplasia (BE) as well as associated BE and squamous cell carcinomas. We aimed to give an indication for the carcinogenic process of EACs with respect to a cancer stem cell (CSC) hypothesis. Materials and methods Patients and Tumor Specimen Surgical specimen from altogether 70 patients having undergone primary surgical resection for esophageal cancer between January 2001 and June 2004 with complete (R0) resection, were included in our study. Patients with preoperative antineoplastic therapies (chemoradiation/chemotherapy) were excluded. The material was archival formalin-fixed, paraffin-embedded tissue from routine histopathologic work-up. Formalin-fixation and paraffin-embedding had been performed under standardized conditions.

The membrane was then washed, blocked with 5% (wt/vol) blocking a

The membrane was then washed, blocked with 5% (wt/vol) blocking agent (non-fat skimmed milk), and incubated with a primary antibody against Omp33 obtained from mouse (INIBIC, A Coruña). Proteins were visualized by incubation with horseradish peroxidase-conjugated secondary antibody, followed by enhanced chemiluminescence ECL Plus (Amersham Pharmacia Biotech) and detected with the LAS3000 chemiluminescence detector (Fujifilm). Acknowledgements and Funding The present study was supported by grants from SERGAS (PS08/24 and

PS07/90) and INCITE 08CSA064916PR from the Xunta de Galicia, by the Spanish Network for Research in Infectious Diseases RD06/0008/0025, and by grants PI081613 and PS09/00687 LY2109761 datasheet from the Instituto de Salud Carlos III (Madrid). J. Aranda is in receipt of a Selleck LY3023414 Sara Borrell post-doctoral grant from the Instituto de Salud Carlos III (Madrid). M. Poza and B. Gómez are in receipt of Isidro Parga Pondal postdoctoral grants from the Xunta de Galicia. S. Rumbo and C. Rumbo are in receipt of pre-doctoral

grants from the Instituto de Salud Carlos III (Madrid). References 1. Munoz-Price LS, Weinstein RA: Acinetobacter infection. N Engl J Med 2008,358(12):1271–1281.PubMedCrossRef 2. Peleg AY, Seifert H, Paterson DL: Acinetobacter baumannii : emergence of a successful pathogen. Clin Microbiol Rev 2008,21(3):538–582.PubMedCrossRef 3. Naiemi NA, Duim B, Savelkoul PH, Spanjaard L, de Jonge E, Bart A, Vandenbroucke-Grauls CM, de Jong MD: Widespread transfer of resistance genes between bacterial species in an intensive care unit: implications for hospital epidemiology. J Clin Microbiol 2005,43(9):4862–4864.PubMedCrossRef 4. Fournier PE, Richet H: The epidemiology and control of Acinetobacter baumannii in health care facilities.

Clin Infect Dis 2006,42(5):692–699.PubMedCrossRef 5. Coyne S, Guigon G, Courvalin P, Perichon B: Screening and quantification of the expression of learn more antibiotic resistance genes in Acinetobacter baumannii MYO10 with a microarray. Antimicrob Agents Chemother 2010,54(1):333–340.PubMedCrossRef 6. Smith MG, Gianoulis TA, Pukatzki S, Mekalanos JJ, Ornston LN, Gerstein M, Snyder M: New insights into Acinetobacter baumannii pathogenesis revealed by high-density pyrosequencing and transposon mutagenesis. Genes Dev 2007,21(5):601–614.PubMedCrossRef 7. Adams MD, Goglin K, Molyneaux N, Hujer KM, Lavender H, Jamison JJ, MacDonald IJ, Martin KM, Russo T, Campagnari AA, et al.: Comparative genome sequence analysis of multidrug-resistant Acinetobacter baumannii . J Bacteriol 2008,190(24):8053–8064.PubMedCrossRef 8. Vallenet D, Nordmann P, Barbe V, Poirel L, Mangenot S, Bataille E, Dossat C, Gas S, Kreimeyer A, Lenoble P, et al.: Comparative analysis of Acinetobacters: three genomes for three lifestyles. PLoS One 2008,3(3):e1805.PubMedCrossRef 9. Fournier PE, Vallenet D, Barbe V, Audic S, Ogata H, Poirel L, Richet H, Robert C, Mangenot S, Abergel C, et al.

To obtain the 5′

To obtain the 5′ flanking region, the primers AP1/CasR20 and AP2/CasW-E70-R04 were used for

PCR1 and PCR2, respectively. To obtain the 3′ flanking region, the primers AP1/CasF9 and AP2/CasW-E70-F04 were used for PCR1 and PCR2, respectively. PCR reactions were performed in 1× buffer containing 1.5 mM of MgCl2, 200 μM of dNTPs, 200 nM of the #Protein Tyrosine Kinase inhibitor randurls[1|1|,|CHEM1|]# adaptor, 0.2 μM of the Cas-specific primer and 0.5 U of Taq DNA polymerase (Eurobio, Courtaboeuf, France). All PCRs were conducted under the following conditions: an initial denaturation step (4 min at 95 °C), then 40 cycles (30 s at 95 °C, 30 s at 58 °C, 2 min at 72 °C) and a final extension step (72 °C for 5 min). PCR products migrating as a single unique band after electrophoresis

on an agarose gel were directly sequenced using nested Cas3-specific primers: CasW-E70-R01 for the 5′ flanking region and CasW-E70-F05 for the 3′ flanking region. A new set of primers (CasF20 and CasR28) was designed from both ends of the 5′ and 3′ flanking sequences and used to amplify the complete Cas3 or Cas4 sequence from isolates E70, E78, E79 and E139 using https://www.selleckchem.com/products/nct-501.html the AccuPrime™ Pfx proofreading DNA polymerase (Invitrogen, Paisley, UK) according to the manufacturer’s recommendations. All of the primers used in this study are listed in the Electronic Supplementary Material ESM 2. Bioinformatics All nucleotide and amino acid sequence analyses, alignments and annotations were conducted using the Geneious Pro program (Drummond et al. 2011). Homology searches were performed using the Blast program in the NCBI database. A phylogenetic tree of the cassiicolin gene diversity was constructed using MEGA5 software (Tamura et al. 2007) by the Neighbor-Joining method (Saitou and Nei 1987). The analysis involved six nucleotide sequences: JF915169, JF915170, JF915171,

JF915172, GU373809 and EF667973, for isolates E70, E78, E79, E139, CC004 and CCP respectively. The codon positions included in the analysis were 1st+2nd+3rd+Noncoding. All positions containing gaps and missing data were eliminated. There was a total of 574 positions in the final dataset. A bootstrap test of 1000 replicates was performed to obtain the percentage in which the associated taxa clustered together (Felsenstein 1985). The evolutionary PD184352 (CI-1040) distances were computed using the p-distance method (Nei and Kumar 2000), and the results were expressed as the number of base differences per site. The synonymous (d S ) and non-synonymous (d N ) substitution rates were calculated by codeml in the PAML package (Goldman and Yang 1994). The prediction of the signal peptide in the protein was performed using SignalP software, version 3.0 (Bendtsen et al. 2004), and the program TMHMM, version 2.0, was used to check for the presence of transmembrane spanning regions in the protein (Krogh et al. 2001). The ProtComp program (version 9.0; http://​www.​softberry.​com) was used to predict the subcellular localization of the protein.

Conflict of interest The authors declare that they have no confli

Conflict of interest The authors declare that they have no conflict of interest. Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial RG-7388 order License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. References Berguer R, Forkey DL, Smith WD (1999) Ergonomic problems associated with laparoscopic surgery. Surg Endosc 13(5):466–468CrossRef

Bousquet J, Flahault A, Vandenplas O, Ameille J, Duron JJ, Pecquet C, Chevrie K, Annesi-Maesano I (2006) Natural rubber latex allergy among health care workers: a systematic review of the evidence. J Allergy Clin Immunol 118:447–454CrossRef Conzett-Baumann K, Jaggi GP, Hüsler A, Hüsler J, Beer JH (2009) The daily walking distance of young doctors and their body mass index. Eur J Int Med 20(6):622–624 Cunningham C, Flynn T, Blake C (2006) Low back pain and occupation among Adavosertib cell line Irish health service workers. Occup Med 56:447–454CrossRef EFILWC (2007) Fourth European working conditions survey. European Foundation for the Improvement of Living and Working Conditions, Dublin. ISBN

92-897-0974-X European Communities (2004) Work and health in the EU, a statistical GDC 0068 portrait. European Communities Failde I, Gonzalez JL, Novalbos JP, Casais F, Marín J, Elorza J (2000) Psychological and occupational predictive factors for back pain among employees of a university hospital in southern Spain. Occup Med 50:591–596 Fulton-Kehoe D, Franklin G, Weaver M,

Cheadle A (2000) Years of productivity lost among injured workers in Washington State: modeling disability burden in workers’ compensation. Am J Ind Med 37:656–662CrossRef ID-8 Johnston WK, Hollenbeck BK, Wolf JS (2005) Comparison of neuromuscular injuries to the surgeon during hand-assisted and standard laparoscopic urologic surgery. J Endourol 19(3):377–381CrossRef Joshi R, Reingold AL, Menzies D, Pai M (2006) Tuberculosis among health care workers in low-and middle-income countries: a systematic review. PLoS Med 3:e494CrossRef Karahan A, Kav S, Abbasoglu A, Dogan N (2009) Low back pain: prevalence and associated risk factors among hospital staff. J Adv Nurs 65:516–524CrossRef Labour statistics (2005) Workplace injuries and illnesses in 2005. Department of labour, United States Sluiter JK (2006) High-demand jobs: age-related diversity in work ability? Appl Ergon 37:429–440CrossRef Sluiter JK, Frings-Dresen MH (2007) What do we know about ageing at work? Evidence-based fitness for duty and health in fire fighters. Ergonomics 50:1897–1913CrossRef Smith DR, Wei N, Zhang YJ, Wang RS (2006) Musculoskeletal complaints and psychosocial risk factors among physicians in mainland China.

4%) and the high/positive expression was in 739 patients (55 6%)

4%) and the high/positive expression was in 739 patients (55.6%). It seemed that patients bearing low/negative BRCA1 had a higher ORR to platinum-based chemotherapy than those bearing high/positive BRCA1 level (48.9% vs 38.1%, OR = 1.70, 95%CI = 1.32-2.18, I 2 = 44.7%, P = 0.03 for heterogeneity) (Figure 2). No publication bias was observed (P = 0.15). In subgroup analysis based on BRCA1 detection method, there were 13 IHC studies (1066 patients) [16, 17, 19, 21–28, 33] and 4 RT-PCR studies (264 patients) [10, 18, 20, 29], the distribution of low/negative BRCA1 was similarity(IHC vs RT-PCR: 44.5% vs 44.3%). Both of them found

HDAC inhibitor review the significant association (for IHC studies, 50.7% vs 39.0%, OR = 1.54, 95%CI = 1.17-2.00, I 2 = 44.8%, P = 0.03 for heterogeneity; for RT-PCR studies, 43.7% vs 25.0%, OR = 2.91, 95%CI = 1.55-3.83, I 2 = 0.0%, P = 0.52 for heterogeneity), When we stratified studies according to their origin, 13 studies were conducted in HSP990 molecular weight East-Asian [16–25, 27, 28, 33] and only 3 were Caucasian [10, 26, 29]. The low/negative BRCA1 level distribution in Caucasian was lower than East-Asian (38.6% vs 45.4%).The significant association was found in East-Asian population rather than Caucasian: for East-Asian, 51.0% vs 36.0%, OR = 1.68, 95%CI = 1.30-2.19, I 2 = 39.9%, P = 0.04 for heterogeneity; for Caucasian, 39.8% vs 33.4%, OR = 1.77, 95%CI = 0.50-6.28,

I 2 = 63.6%, P = 0.06 for heterogeneity. However, the relationship between BRCA1 level and ORR in Caucasian population could not be determined as the sample size was not large enough. 7 studies consisted of 3 East-Asian [18, 30, 32] and 4 Caucasian [10, 26, 29, 31] including NU7026 nmr 733 patients were used to analyzed the OS. The significant association between BRCA1 expression and OS in platinum-based treatment was detected. Patients bearing low/negative BRCA1 was more likely to have longer survival time. (HR = 1.58, 95%CI = 1.27-1.97, I 2 = 48.4%, P = 0.03 for heterogeneity) (Figure 3), no publication bias was observed (P = 0.13). EFS data

were available for 5 Tenoxicam studies [26, 29, 31, 32, 36] with 599 patients (3 were PFS [26, 29, 32], one was DFS [31] and the other one was TTP [36]),only one study was about East-Asian[32]. It seemed that patients with low/negative BRCA1 had longer EFS than those with high level, even there was no publication bias, but heterogeneity existed between studies. (HR = 1.60, 95%CI = 1.07-2.39) (I 2 = 54.5%, P = 0.02 for heterogeneity) (Figure 4). 2. Taxol-based chemotherapy Since only 2 studies [35, 36] presented the sufficient data of OS and EFS that ensured us to conducted meta-analysis. We didn’t evaluate the relationship between BRCA1 expression and OS/EFS. In ORR analysis, we applied 4 eligible studies (2 East-Asian and 2 Caucasian) [34–37] in our meta-analysis.

Nucleic Acids Res 1994, 22:4673–4680 PubMedCrossRef Authors’ cont

Nucleic Acids Res 1994, 22:4673–4680.PubMedCrossRef Authors’ contributions ST coordinated the study, ZD1839 datasheet participated in the concept development and in the assays design, the analysis and interpretation of the results, and drafted the manuscript. MC participated in the concept development and in the assays design, carried out PR-171 sample preparation and optimization of PCR experimental procedures, the analysis and interpretation of the results, and helped with the manuscript

preparation. IML carried out sample preparation and PCR experimental procedures, and helped with analysis and interpretation of the results. ES was involved in the initial study design, participated in sample selection and performed some of the preliminary experiments. All authors read and approved the final manuscript.”
“Background Yersinia enterocolitica

is an important food- and water-borne gastrointestinal agent. It is known to cause a variety of syndromes ranging from JNK phosphorylation mild gastroenteritis to more invasive diseases like terminal ileitis and mesenteric lymphadenitis mimicking appendicitis [1]. Blood transfusion associated septicaemia due to Y. enterocolitica has been reported to have high mortality [2]. Post infectious sequelae include reactive arthritis and erythema nodosum [1]. Y. enterocolitica is classified into six biovars (1A, 1B, 2, 3, 4 and 5) and more than 50 serotypes [3]. On the basis of pathogenicity, it has been grouped into highly pathogenic (biovar 1B), moderately pathogenic (biovars 2-5) and the so called non-pathogenic (biovar 1A) biovars. Recently, using comparative phylogenomics, Howard et al [4] suggested that these groups might represent three subspecies of Y. enterocolitica. The biovar 1A strains are quite heterogeneous serologically and have been isolated from a variety

of sources viz. stools of diarrheic humans, animals, food and aquatic sources [5]. The biovar 1A strains are thought to be non-pathogenic as they lack pYV (plasmid for Yersinia from virulence) plasmid and major chromosomal virulence determinants [1]. However, some biovar 1A strains are known to produce symptoms indistinguishable from that produced by the pathogenic biovars [6, 7]. Y. enterocolitica biovar 1A has also been implicated in nosocomial [8] and food-borne [9] outbreaks. A serotype O:6,30 (biovar 1A) strain was reported to cause placentitis and abortion in pregnant ewes [10]. Y. enterocolitica biovar 1A was the most predominant biovar isolated from both livestock and humans during a survey in Great Britain in 1999-2000 and surely needs to be studied further [11]. Several recent studies suggest that these strains might possess novel, as yet unidentified, virulence determinants [12–16]. Serological heterogeneity notwithstanding, Y.

Conjugated organic molecules such as these have been widely used

Conjugated organic molecules such as these have been widely used in organic light-emitting diodes to improve device performance by controlling

the hole injection barrier [25]. Efficient doping of organic semiconductors, of carbon nanotubes, and of graphene has been demonstrated. We demonstrate herein a novel carrier doping method for chemically derived graphene using radical-assisted conjugated organic molecules in the liquid phase. It is expected that liquid-phase chemical interactions between graphene and conjugated organic molecules induce high doping efficiency. Absorbance measurements provide direct LY3023414 molecular weight evidence for charge-transfer (CT) interactions between graphene and radicalized TCNQ molecules in an organic solvent. Raman spectroscopy and ultraviolet photoelectron spectroscopy (UPS) have also been used to elucidate the effects of doping on doped graphene films, which showed improvements

in resistivity of two orders of magnitude with highly stable doping effect. Previous attempts at carrier doping for chemically derived graphene have never decreased the resistivity by more than one order of magnitude [26]. The doping mechanism of the chemical doping is investigated using first-principles calculation based on density functional theory. Our doping method click here is compatible with the wet production technique of chemical-exfoliated graphene. The doped graphene films can be formed by the all-wet process via the radical-assisted chemical doping method as demonstrated in this work. Methods Preparation and OSI-027 in vivo reduction of graphene oxide Chemically derived graphene was synthesized using a modified version of Hummer’s

method, a well-known approach to producing monolayered graphene via the liquid-phase exfoliation of graphite oxide, as described previously in the literature [27]. Natural graphite powder was donated by SEC Carbon Ltd. (Tokyo, Japan). Celastrol All other chemicals were purchased from Kanto chemical Co. Ltd. (Sakado, Japan) and used directly without further purification. Chemically derived graphene was synthesized by the modified Hummer’s method, a well-known approach to produce monolayered graphene via liquid-phase exfoliation of graphite oxide. Natural graphite powder (SEC Carbon SNO-30) was oxidized in KMnO4 and H2SO4. After centrifugation, the resulting graphite oxide was exfoliated into graphene oxide (GO) by ultra-sonication (100 W, 30 min, 60°C). Then, a GO aqueous dispersion was produced by centrifugation and dialysis to neutralize a pH. A reduction step of GO into graphene plays an essential role to determine the electrical properties of the resulting graphene films. GO was reduced as follows: GO was dispersed in aqueous solution containing N2H4, a strong reductant, with NH3 to adjust pH.

BMC Microbiol 2001,1(1):5 PubMedCrossRef 30 Wright ADG, Ma X, Ob

BMC Microbiol 2001,1(1):5.PubMedCrossRef 30. Wright ADG, Ma X, Obispo NE: Methanobrevibacter phylotypes are the

dominant methanogens in sheep from Venezuela. Microbial Ecol 2008,56(2):390–394.CrossRef 31. Samuel BS, Gordon JI: A humanized gnotobiotic mouse model of host-archaeal-bacterial mutualism. Proc Natl Acad Sci USA 2006,103(26):10011–10016.PubMedCrossRef 32. Zhao Y, Boone DR, Mah RA, Boone JE, Xun L: Isolation and characterization of Methanocorpusculum labreanum sp. nov. from the LaBrea Tar Pits. Int J Syst Bacteriol 1989,39(1):10–13.CrossRef 33. Garcia JL, DNA Damage inhibitor Ollivier B, Whitman WB: The order Methanomicrobiales. Prokaryotes 2006, 3:208–230.CrossRef 34. Ohkuma M, Noda S, EPZ015938 datasheet Horikoshi K, Kudo T: Phylogeny of symbiotic methanogens in the gut of the termite Reticulitermes speratus. FEMS microbiol lett 2006,134(1):45–50.CrossRef 35. Purdy KJ: The distribution and diversity of Euryarchaeota in termite guts. Adv Appl Microbiol 2007, 62:63–80.PubMedCrossRef 36. Barber RD: Methanogenesis: ecology. New York: John Wiley & Sons; 2007. doi:10.1002/9780470015902.a0000475.pub2 37. Clauss M, Frey R, Kiefer B, Lechner-Doll M, Loehlein W, Polster C, Rössner G, Streich WJ: The maximum attainable body size of herbivorous mammals: morphophysiological constraints on foregut, and adaptations of hindgut fermenters.

Oecologia 2003,136(1):14–27.PubMedCrossRef 38. Facey HV, Northwood KS, Wright ADG: Molecular Diversity of methanogens in fecal samples from captive Sumatran orangutans ( pongo abelii) . Amer J selleck products Primatol 2012,74(5):460–468.CrossRef 39. Hofmann R: Evolutionary steps of ecophysiological adaptation and diversification of ruminants: a comparative view of their digestive system. Oecologia 1989,78(4):443–457.CrossRef 40.

Oftedal OT, Baer DJ, Allen ME: The feeding and nutrition of herbivores. Chicago (USA): University of Chicago Press; 1996. 41. Dridi B, Fardeau ML, Ollivier B, Raoult D, Drancourt M: Methanomassiliicoccus luminyensis gen. nov., sp. nov., a methanogenic archaeon isolated from human faeces. Int J Syst Evol Microbiol 2012,62(Pt 8):1902–1907.PubMedCrossRef Benzatropine Competing interests The authors declare that they have no competing interests. Authors’ contributions YL designed the study, carried out the sequence alignment and drafted the manuscript. ADGW participated in the sequence alignment and performed the statistical analysis. YL participated in the design of the study. HL participated in the sequence alignment. QY participated in the design of the study. LL and MY helped to draft the manuscript. All authors read and approved the final manuscript.”
“Background Salmonella is the most common cause of bacterial food-borne illness in the U.S. and is estimated to annually cause over 1 million cases, 19,000 hospitalizations, 350 deaths, and $2.6 billion in social costs [1, 2].

Biochim Biophys Acta 25:220–221PubMedCrossRef Crane FL, Ehrlich B

Biochim Biophys Acta 25:220–221PubMedCrossRef Crane FL, Ehrlich B, Kegel LP (1960) Plastoquinone reduction in illuminated chloroplasts. Biochem Biophys Res Commun 3:37–40CrossRef learn more Crane FL, Henninger MD, Wood PM, Barr R (1966) Quinones in chloroplasts. In: Goodwin TW (ed) Biochemistry of chloroplasts. SC75741 chemical structure Academic Press, London, pp 133–151 Craven R (1931) A sensitive color reaction for certain quinones. J Chem Soc 1931:1605–1606 Das BC, Lounasmaa M, Tendille M, Lederer E (1967) The structure

of the plastoquinones B and C. Biochem Biophys Res Commun 26:211–215PubMedCrossRef Dilley RA (1964) Thin layer chromatography of naturally occurring quinones and hydroquinones. Anal Biochem 7:240–246PubMedCrossRef Dilley RA, Crane FL (1963) Light-induced changes of α-tocopherylquinone in spinach chloroplasts. Biochim Biophys Acta 75:142–143PubMedCrossRef Donaldson KO, Nason A, Garrett RH (1958) A requirement for alpha tocopherol in mitochondria DPNH oxidase. J Biol Chem 233:566–570PubMed Dunphy PJ (1971) Phootosensitised oxidation of terpenes

and its biological consequences. Chem Indust 1971:731–732 Eck VH, Trebst A (1963) Uber die Konstitution eines weiteren Plastochinons und seines dimeren aus Kastanienblattern. Z Naturforsch 18b:446–451 Egger K (1965) Die verbreitung von vitamin K1 und Plastochinone in Pflanzen. Planta 64:41–61CrossRef Egger K, Kleinig H (1967) Die plastochinonanalogen-ein kritischer vergleich. Zeit Pflanzenphysiol 56:113–121 Erickson JM, Pfister K, Rahirer M, Togasaki RK, Mets L, Rochaix JD (1989) Molecular and biophysical analysis of herbicide selleck chemical resistant mutants of Chlamydomonas reinhardtii. Plant Cell 1:361–371PubMedCrossRef Folkers K, Shunk CH, Linn BO, Trenner NR, Wolf DE,

Hoffman CH, Page AC, Koniuszy FR (1961) Coenzyme Q. XXIII. Organic and biological studies. In: Wolstenholme GEW, O’Connor CM (eds) Quinones in electron transport. Churchill, London, pp 100–126CrossRef Friend J, Redfearn ER (1963) Studies of plastoquinone-2. Oxidation-reduction reactions of plastoquinone in isolated chloroplasts. Phytochemistry 2:397–405CrossRef Frigerio S, Campoli C, Zorzan S, Fantoni LI, Crosetti C, Drepper F, Haehnel W, Cativelli L, Florfenicol Morosinotto T, Bassi R (2007) Photosynthetic antenna size in higher plants is controlled by the plastoquinone redox state at the post transcriptional rather than transcriptional level. J Biol Chem 282:29457–29469PubMedCrossRef Friis P, Daves GD, Folkers K (1967) New epoxy ubiquinones. Biochemistry 6:3618–3624PubMedCrossRef Gille L, Nohl H (2000) The existence of a lysosomal redox chain and the role of ubiquinone. Arch Biochem Biophys 375:347–354PubMedCrossRef Golbeck JH (ed) (2006) Photosystem I: the light-driven plasocyanin:ferredoxin oxidoreductase. In: Govindjee (Series Editor) Advances in photosynthesis and respiration, vol 24.

Methods Cell Biol 1995, 46: 29–39 CrossRefPubMed 15 Bresin A, Ia

Methods Cell Biol 1995, 46: 29–39.CrossRefPubMed 15. Bresin A, Iacoangeli A, Risuleo G, Scarsella G: Ubiquitin dependent proteolysis is activated in apoptotic fibroblasts in culture. Mol Cell Biochem 2001, 220: 57–60.CrossRefPubMed 16. Berardi V, Ricci F, Castelli M, Galati G, Risuleo G: Resveratrol exhibits a strong cytotoxic activity in cultured cells and has an antiviral action against polyomavirus: potential clinical use. J Exp Clin Cancer Res 2009,

28: 96.CrossRefPubMed 17. Abbas K, Breton J, Drapier JC: The interplay between nitric oxide and peroxiredoxins. Immunobiology 2008, 213: 815–822.CrossRefPubMed 18. Quan LJ, Zhang B, Shi WW, Li HY: Hydrogen peroxide in plants: a versatile molecule of the reactive oxygen species network. J Integr Plant Biol 2008, 50: 2–18.CrossRefPubMed 19. Guilpain P, Servettaz A, Batteux F, Guillevin L, Mouthon selleck kinase inhibitor L: Natural and disease associated anti-myeloperoxidase (MPO) autoantibodies. Autoimmun Rev 2008, 7: 421–425.CrossRefPubMed 20. Pellegrini M, Baldari CT: Apoptosis and oxidative stress-related diseases: the p66Shc connection.

Curr Mol Med 2009, 9: 392–398.CrossRefPubMed 21. Hassa PO: The molecular “”Jekyll and Hyde”" duality of PARP1 in cell death and cell survival. Front Biosci 2009, 14: 72–111.CrossRefPubMed 22. Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992, 119: 493–501.CrossRefPubMed 23. Grasl-Kraupp B, Ruttkay-Nedecky B, Koudelka H, Bukowska K, Bursch W, Schulte-Hermann R: In situ detection of fragmented DNA (TUNEL assay) JPH203 solubility dmso fails to discriminate among apoptosis, necrosis, and autolytic cell death: a cautionary note. Hepatology 1995, 21: 1465–1468.PubMed 24. BIRB 796 Negoescu A, Lorimier P, Labat-Moleur F, Drouet C, Robert C, Guillermet C, Brambilla C, Brambilla E: In situ apoptotic cell labeling by the TUNEL method: improvement and evaluation on cell preparations. J Histochem Cytochem 1996, 44: 959–68.PubMed 25. Negoescu A, Guillermet C, Lorimier P, Brambilla E, Labat-Moleur F: TUNEL apoptotic cell detection in tissue sections:

critical evaluation and improvement. Biomed Pharmacother 1998, 52: 252–258.CrossRefPubMed 26. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG: Specific proteolytic unless cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 1993, 53: 3976–3985.PubMed 27. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, Munday NA, Raju SM, Smulson ME, Yamin T-T, Yu VL, Miller DK: Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995, 376: 37–43.CrossRefPubMed 28. Germain M, Affar EB, D’Amours D, Dixit VM, Salvesen GS, Poirier GG: Cleavage of automodified poly(ADP-ribose)polymerase during apoptosis. J Biol Chem 1999, 274: 28379–28384.CrossRefPubMed 29.